IndraLab

Statements

Rosiglitazone inhibits IKBKB. 1 / 1

| 1

reach

"Rosiglitazone treatment significantly improved hepatic insulin sensitivity and inhibited the IKK-beta, NF-kappaB, and Ser307p-IRS-1 expressions in the liver (P < 0.05)."

25036911

INDRA sources:

Colored badges next to statement headings correspond to evidence counts from knowledge sources, as shown below. Badges to the left of the | separator correspond to curated knowledge base sources, and badges to the right of it correspond to machine reading systems.

IndraLab

Statements

Rosiglitazone inhibits IKBKB. 1 / 1

INDRA sources:

Databases

Reading